Patents Examined by Snigdha Maewall
  • Patent number: 11433031
    Abstract: A method for manufacturing a preparation which contains acetaminophen at a high content, in particular, a miniaturized tablet (conventional tablets, sustained-release tablets, etc.) which have excellent elution properties, preferable hardness and high drug content uniformity, and a premix drug substance of acetaminophen which has improved manufacturability. According to the method in which acetaminophen having a preset particle size is used for manufacturing a preparation, the flowability of acetaminophen can be improved so that secondary agglomeration can be suppressed and manufacturing efficiency can be elevated. Thus, this method is highly useful for manufacturing an acetaminophen preparation having improved administrability, for example, a reduced size.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: September 6, 2022
    Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Sakamoto, Kunio Komai, Kenji Sakakibara, Hirokazu Banba, Kiyoshi Fukuda
  • Patent number: 11433033
    Abstract: The present invention includes a low dose and sustained release formulation of a mitochondrial uncoupling agent The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof.
    Type: Grant
    Filed: July 22, 2020
    Date of Patent: September 6, 2022
    Assignee: YALE UNIVERSITY
    Inventors: Gerald I. Shulman, Rachel Jamison Perry
  • Patent number: 11419876
    Abstract: Methods for preventing feedlot bovine respiratory diseases employing mirtazapine as pre-shipment treatments are disclosed. Compositions are further disclosed. Beneficially, the methods and compositions provide safe and cost-effective management of a costly disease.
    Type: Grant
    Filed: August 10, 2020
    Date of Patent: August 23, 2022
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Steven Alan Carlson, Tim Day
  • Patent number: 11420931
    Abstract: Compositions and methods useful in administering nucleic acid based therapies, for example association complexes such as liposomes and lipoplexes are described.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: August 23, 2022
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Akin Akinc, Jayaprakash K. Nair, Muthusamy Jayaraman, Martin Maier
  • Patent number: 11413235
    Abstract: Described herein are liquid compositions, comprising an ethoxylated amine of a fatty acid, an organic solvent, and an acid.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: August 16, 2022
    Assignee: Colgate-Palmolive Company
    Inventors: Turan Matur, Sylvia Hess, Andre Brunella, Thomas Schollbach
  • Patent number: 11395848
    Abstract: Described herein are methods and compositions for treating diabetes mellitus, concerning oral pharmaceutical compositions comprising insulin in combination with a GLP-1 analogue.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: July 26, 2022
    Assignee: ORAMED LTD.
    Inventor: Miriam Kidron
  • Patent number: 11395800
    Abstract: An object of the present invention is to provide a pharmaceutical tablet having high tensile strength and excellent in immediate disintegrability. The pharmaceutical tablet of the present invention is obtained by a direct compression method, and contains an active ingredient, a polyvinyl alcohol resin, and a plasticizer other than water, wherein a content of the plasticizer is 1 to 8 parts by weight with respect to 100 parts by weight of the polyvinyl alcohol resin.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: July 26, 2022
    Assignee: MITSUBISHI CHEMICAL CORPORATION
    Inventors: Chizuko Furo, Ayaka Kobayashi, Hirofumi Takeuchi, Yoshiko Takeuchi
  • Patent number: 11382865
    Abstract: The present invention refers to a pharmaceutical preparation (10) comprising a first pharmaceutical composition having a matrix material and pharmaceutically active ingredients distributed within the matrix material, wherein the first pharmaceutical composition comprises Praziquantel, Pyrantel and Febantel as pharmaceutical active ingredients, wherein the preparation (10) comprises a second pharmaceutical composition having a matrix material and at least one of avermectins and milbemycins such as Moxidectin as pharmaceutically active ingredient distributed within the matrix material, wherein the preparation (10) is provided in a multi-layer structure such, that the first composition is provided in a first layer (12) and the second composition is provided in a second layer (14), wherein the first layer (12) and the second layer (14) are separated by a barrier layer (16) being provided between the first layer (12) and the second layer (14).
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 12, 2022
    Assignee: BAYER ANIMAL HEALTH GMBH
    Inventors: Venkata-Rangarao Kanikanti, Patrick Billian
  • Patent number: 11369630
    Abstract: The present invention describes the use of a pharmaceutically-acceptable formulation of magnesium chloride to treat muscle spasm, strain and sprain.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: June 28, 2022
    Assignee: FLEX-IT MG LLC
    Inventor: Harvey Hoffenblum
  • Patent number: 11351118
    Abstract: Certain embodiments of the invention provide methods of ameliorating an infusion reaction in a mammal in need thereof.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: June 7, 2022
    Assignee: ARBUTUS BIOPHARMA CORPORATION
    Inventors: Jeffrey P. Bechard, Wayne J. Wallis
  • Patent number: 11338007
    Abstract: Disclosed are pharmaceutical compositions comprising three antiviral compounds. In particular, the pharmaceutical compositions comprise an effective amount of velpatasvir, an effective amount of sofosbuvir, and an effective amount of voxilaprevir. Also disclosed are methods of use for the pharmaceutical composition.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 24, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Ben Chal, Elham Nejati, Rowchanak Pakdaman, Dimitrios Stefanidis
  • Patent number: 11331256
    Abstract: The present disclosure relates to a cosmetic composition for blocking fine dust. The composition according to the present disclosure can fundamentally prevent problems due to fine dust by reducing the attachment rate of fine dust attached to skin.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 17, 2022
    Assignee: LG HOUSEHOLD & HEALTH CARE LTD.
    Inventors: Seong-Cheon Lee, Hyeong-Jin Cho, Ki-Young Kim, Eui-Taek Jeong, Yu-Mi Kim, Nae-Gyu Kang
  • Patent number: 11331252
    Abstract: A whitening dentifrice composition includes a blue coloring agent, a zinc salt, and an orally acceptable vehicle. The blue coloring agent is selected from the group consisting of a blue pigment and a blue dye. The blue pigment has a blue to blue-violet color with a hue angle in the CIELAB system ranging from 200 degrees to 320 degrees. The whitening dentifrice composition provides a greater whitening benefit to a tooth surface in comparison to a dentifrice composition that does not contain the zinc salt.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: May 17, 2022
    Assignee: Colgate-Palmolive Company
    Inventors: Agnieszka Kocinska, Suman Chopra, Jennifer Gronlund
  • Patent number: 11331283
    Abstract: A pharmaceutical composition containing cinacalcet or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. A pharmaceutical composition containing cinacalcet or pharmaceutically acceptable salts thereof having a particle size distribution D90 equal to or less than 20 ?m, D50 equal to or less than 10 ?m, and D10 equal to or less than 5 ?m and one or more and binders in an amount of 0.9% w/w or less, relative to the total weight of composition, where the composition is not free of binder and that the total amount of binder does not exceed 0.9% w/w relative to the total weight of the composition.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: May 17, 2022
    Assignee: UNICHEM LABORATORIES LTD
    Inventors: Dhananjay Sathe, Srikant Pimple, Pravin Kumar Maurya
  • Patent number: 11324681
    Abstract: Compositions that include: from 5 wt-% to 70 wt-% of one or more plant based oils based on the total weight of the composition; from 35 wt-% to 95 wt-% of an aqueous phase based on the total weight of the composition; not greater than 7.5 wt-% of one or more surfactants based on the total weight of the composition; and not greater than 3 wt-% of a viscosity modifier of, wherein the composition has a pH from 4.5 to 9.5, the composition is an oil in water (o/w) emulsion, and the composition is edible. Methods of utilizing disclosed compositions are also included.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: May 10, 2022
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Katie F. Wlaschin, Amanda C. Engler, Hannah C. Cohen, Yizhong Wang, Tao Gong, Tiffany T. Ton, Joel D. Oxman, Jie Yang
  • Patent number: 11291702
    Abstract: An intra-oral, nanoemulsion blend is provided that enhances liver and toxin excretion performance in mammals when orally administered. A solid powder toxin binding composition also is provided that may be used to irreversibly bind the toxins reaching the bowel so that once the toxins are excreted into the bowel, they may not be reabsorbed, and are thus eliminated. A method of administering the nanoemulsion blend and the toxin binding composition to enhance toxin excretion also is described. The nanoemulsion blend is ingestible and edible.
    Type: Grant
    Filed: April 15, 2020
    Date of Patent: April 5, 2022
    Assignee: Quicksilver Scientific, Inc.
    Inventors: Christopher W. Shade, Steven Tieu
  • Patent number: 11291629
    Abstract: An object of the invention is to provide a mucoadhesive oral preparation having high drug absorption rate and rapid drug release rate. The means for solving the problem is a mucoadhesive oral preparation having (a) a basal layer substantially consisting of a water-insoluble material, (b) a drug layer locating above the basal layer and containing a drug but not containing mucoadhesive material, and (c) an adhesive portion locating on a portion of the surface of the drug layer side of the oral formulation and containing mucoadhesive material.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: April 5, 2022
    Assignee: BIOSERENTACH CO., LTD.
    Inventor: Kanji Takada
  • Patent number: 11268952
    Abstract: The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers, savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.
    Type: Grant
    Filed: January 16, 2020
    Date of Patent: March 8, 2022
    Assignee: Firmenich Incorporated
    Inventors: Catherine Tachdjian, Andrew P. Patron, Sara L. Adamski-Werner, Farid Bakir, Qing Chen, Vincent Darmohusodo, Stephen Terrence Hobson, Xiaodong Li, Ming Qi, Daniel H. Rogers, Marketa Rinnova, Guy Servant, Xiao-Qing Tang, Mark Zoller, David Wallace, Amy Xing, Klaus Gubernator
  • Patent number: 11260009
    Abstract: This invention relates to high-water oral care compositions comprising a basic amino acid or salt thereof, together with a precipitated calcium carbonate, glycerol, and to methods of using and of making these compositions.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: March 1, 2022
    Assignee: Colgate-Palmolive Company
    Inventors: Enzo Utima, Abraham Cazes, Erico Prat
  • Patent number: 11260050
    Abstract: The present invention relates to a method of a) treating any of depression induced by chronic stress; depression in a subject afflicted with PTSD; anxiety induced by chronic stress; anxiety in a subject afflicted with PTSD; cognitive impairment induced by chronic stress; altered morphology and/or reduced number of GFAP+ cells in hippocampus and/or frontal cortex induced by chronic stress; working memory impairment in a subject afflicted with PTSD; b) inhibiting or reversing loss of GFAP+ cells in hippocampus and/or frontal cortex induced by chronic stress; c) decreasing consolidation of contextual fear memory in a subject afflicted with PTSD; d) enhancing extinction of fear memory in a subject afflicted with PTSD; or e) increasing calcineurin A expression in a subject afflicted with PTSD using a combination of cotinine and an antioxidant.
    Type: Grant
    Filed: February 16, 2018
    Date of Patent: March 1, 2022
    Assignees: UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS, UNIVERSIDAD SAN SEBASTIAN
    Inventor: Valentina Echeverria Moran